Skip to content

Comparative analysis on the curative effect between umbilical cord mesenchymal stem cell transplantation and anti-diabetic treatment

Comparative analysis on the curative effect between umbilical cord mesenchymal stem cell transplantation and anti-diabetic treatment

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002868
Enrollment
Unknown
Registered
2012-12-23
Start date
2011-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

A:umbilical cord mesenchymal stem cell transplantation
B:anti-diabetic drugs or insulin injection

Sponsors

General Hospital of Chinese People's Armed Police Forces
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria included the following: the patients were between the ages of 18 and 70 years, male or female; they had poor glycemic control with recent anti-diabetic therapies, including drugs and/or insulin injection for at least three months; they had a negative result in testing for the glutamic acid decarboxylase antibody; they had not been pregnant or nursing; they had a fasting blood glucose (FBG) level >=7.0 mmol/L and HbA1c>=7%; and they had a good organic sufficiency, including heart, liver, kidney and lung, to receive interventional therapy.

Exclusion criteria

Exclusion criteria: acute or chronic infections; any malignancies; hematological diseases or coagulopathy; known immunosuppressive disease (e.g., acquired immunodeficiency); acute or chronic pancreatitis; and a history of thoracic or abdominal aorta diseases

Design outcomes

Primary

MeasureTime frame
Glycated hemoglobin;C-peptide;Glycemia;Beta-cell function;

Secondary

MeasureTime frame
Insulin requirement and oral hypoglycemic drugs;Immunologic cells tests;Inflammatory cytokines (IL-1 beta, IL-6, IL-10 and TNF);

Countries

China

Contacts

Public ContactYihua an
riveran@163.com+86 010-57976848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026